CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

202207Orig1s000

CHEMISTRY REVIEW(S)

NDA 202207

Kit for the preparation of Lymphoseek® (technetium Tc 99m tilmanocept) Injection Navidea Biopharmaceuticals, Inc. 425 Metro Place North Suite 300 Dublin, OH 43017

Summary of the Basis for the Recommended Action from Chemistry, Manufacturing, and Controls

Indication: (b) (4) localization of lymph nodes in pts with melanoma, and with breast cancer

Presentation: The drug product

Consults

0011001100			
	Biopharm Recommendation	on:	NA
	Establishments Evaluation	n Report:	Acceptable
	EA -	Categorical e	exclusion per
		21CFR25.31	granted
	Statistics –	N/A	-
	Methods Validation –	Not requeste	ed
	Clinical Pharm –	Acceptable	
	Microbiology –	Acceptable	
	Pharm Toxicology -	NA	
	DMEPA	Proprietary r	name acceptable
Original Sul	bmission:	August 10, 2	011
Post-Approv	al CMC Agreements:	None	

Drug Substance Tilmanocept

^{(b) (4)} has a

dextran (C-10) backbone conjugated with a linker moiety (an amine terminated "leash") that is subsequently coupled with Diethylenetriamine pentaacetic acid (DTPA) and

mannose moieties. The mannose acts as a substrate for the receptor on MBP and the DTPA serves as a chelating agent for radiolabeling with Technetium Tc99m.

Since Tilmanocept has a dextran backbone, it has a molecular weight distribution (b) (4)


carry the amine leash; of those leashes, 3-8 are conjugated to DTPA, 12-20 are conjugated to mannose and 0-17 remain as the free amine. The calculated average molecular weight of tilmanocept will range from 15,281 to 23,45 A re-test of ^{(b) (4)} has been established


Conclusion: Drug substance is satisfactory

Drug product

The drug product (trademark: Lymphoseek®) will be supplied as "kit" containing a sterile lyophilized preparation of Tilmanocept, 0.25 mg (labeled as Tilmanocept Powder) and co-packaged sterile buffer saline diluent (labeled as DILUENT for Lymphoseek). Tilmanocept Powder vial contains non-radioactive ingredients necessary to produce technetium Tc 99m tilmanocept after radiolabeling with technetium Tc 99m solution obtained from a commercially available generator at the clinical site of use. The Tilmanocept powder vial contains sterile, non-pyrogenic, white to off-white powder, of a mixture of 250 mcg (0.25 mg) of tilmanocept, 20 mg trehalose dihydrate, 0.5 mg glycine, 0.5 mg sodium ascorbate, and 0.075 mg, stannous chloride dihydrate. The contents of the vial are lyophilized and stored under nitrogen. The DILUENT for Lymphoseek contains 4.5 mL sterile buffered saline consisting of 0.04% (w/v) potassium phosphate, 0.11% (w/v) sodium phosphate (heptahydrate), 0.50% (w/v) sodium chloride, and 0.40% (w/v) phenol. The pH is 6.8 – 7.2.

The lyophilized formulation provides ^{(b) (4)} lyophilized cake, allowing for quick reconstitution with Sodium Pertechnetate in saline to produce a clear injection solution. Each Tilmanocept powder vial can be radiolabeled with 2.5 - 10 mCi (q.s. 0.35 - 0.7 mL) of sodium pertechnetate solution. The formulation contains ^{(b) (4)}





The provided stability data in the NDA support an expiry dating period of 12 months for the drug product. **Drug product is satisfactory**

Labeling

Package insert and immediate and carton labeling is acceptable, however, due to the complex nature of product preparation for administration the sponsor developed a "poster" for display in the nuclear pharmacy which succinctly describes the product preparation.

Overall Conclusion:

There are no pending CMC review deficiencies. Therefore, from the CMC point of view, the NDA may be approved.

Eric P. Duffy, Ph.D. Director, Division III ONDQA/CDER/FDA This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P DUFFY 02/26/2013

NDA 202207

Kit for the preparation of Lymphoseek[®] (technetium Tc 99m tilmanocept) Injection

Navidea Biopharmaceuticals, Inc. 425 Metro Place North Suite 300 Dublin, OH 43017

Ravindra K. Kasliwal, Ph.D. Division of New Drug Quality Assessment – III Division of Medical Imaging Products





Table of Contents

Ta	ble of Contents	2
Cł	nemistry Review Data Sheet	3
Tł	e Executive Summary	7
I.	Recommendations	7
	A. Recommendation and Conclusion on Approvability	7
	B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	7
II.	Summary of Chemistry Assessments	7
	A. Description of the Drug Product(s) and Drug Substance(s)	7
	B. Description of How the Drug Product is Intended to be Used	8
	C. Basis for Approvability or Not-Approval Recommendation	9
III.	Administrative	9
	A. Reviewer's Signature	9
	B. Endorsement Block	9
	C. CC Block	9
Cł	nemistry Assessment	10

Chemistry Review Data Sheet

1. NDA 202207

- 2. REVIEW #: 3
- 3. REVIEW DATE: 19-Feb-2013
- 4. REVIEWER: Ravindra K. Kasliwal, Ph.D.

5. PREVIOUS DOCUMENTS:

Submission(s)	Document Date
Original	10-Aug-2011
Amendment	04-Nov-2011
Amendment	06-Jan-2012
Amendment	12-Jan-2012
Amendment	13-Feb-2012
Amendment	17-Feb-2012
Amendment	20-Mar-2012
Amendment	30-Mar-2012
Amendment	05-Apr-2012
Amendment (meeting package)	28-Jun-2012
Amendment	06-Jul-2012
Amendment	02-Aug-2012

6. SUBMISSIONS BEING REVIEWED:

Submission	Document Date
Resubmission	31-Oct-2012
Amendment	09-Nov-2012
Amendment	16-Nov-2012
Amendment	12-Feb-2013
Amendment	13-Feb-2013

7. NAME & ADDRESS OF APPLICANT:

Name:	Navidea Biopharmaceuticals, Inc.
Address:	425 Metro Place North, Suite 300, Dublin, OH 43017
Representative:	Rodger Brown, Vice President RA/ QA
Telephone:	614-793-7500 x 142






Chemistry Assessment Section

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: Lymphoseek[®]
- b) Non-Proprietary Name (USAN): technetium Tc99m tilmanocept
- c) Code Name/# (ONDC only): 70-2903
- d) Chem. Type/Submission Priority (ONDC only):
 - Chem. Type: 1
 - Submission Priority: S
- 9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)
- 10. PHARMACOL. CATEGORY: Radiopharmaceutical
- 11. DOSAGE FORM: For Injection
- 12. STRENGTH/POTENCY: 250 micrograms
- 13. ROUTE OF ADMINISTRATION: Intradermal
- 14. Rx/OTC DISPENSED: _X_Rx __OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):</u> _____SPOTS product – Form Completed

X Not a SPOTS product

 CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:



Technetium-⁹⁹Tc, dextran, 3 [(2-aminoethyl) thio]propyl-17-carboxy-10,13,16-tris (carboxymethyl) -8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(Dmannopyranosylthio)ethyl] amino] ethyl] thio]propyl ether.

The molecular formula of technetium Tc 99m tilmanocept is $[C_6H_{10}O_5]_n.(C_{19}H_{28}N_4O_9S^{99m}Tc)_b.(C_{13}H_{24}N_2O_5S_2)_c.(C_5H_{11}NS)_a$ [Where, a = 0-17, b = 12-20, and c = 3-8]

The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454.

CRE

CHEMISTRY REVIEW TEMPLATE



Chemistry Assessment Section

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYP E	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
(b) (4)	Π		(b) (4)	1	Adequate	19-Jul-2012	Reviewed by Ravindra K. Kasliwal, Ph.d. and John Metcalf, Ph.D.
	Ш			4	Adequate	07-Oct-2005	DNF was reviewed for (b) (4) (by Jila Boel, Ph.D.) and was adequate.
	III			4	Adequate	06-Aug-2003	DMF was reviewed for a lyophilized powder product (by Ravindra Kasliwal, Ph.D.) and was adequate.
	V			4	N/A	N/A	The DMF describes ^{(b) (4)} and is reviewed by product quality microbiology.
	Π			1	Adequate	18-Jul-2012	Reviewed by Ravindra K. Kasliwal, Ph.D.
	Ш			3, 4	N/A	N/A	The stopper is used in diluent vial. The stopper is used in many injectable products.

¹Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2-Type 1 DMF

3 - Reviewed previously and no revision since last review

4 - Sufficient information in application

5 - Authority to reference not granted

6 - DMF not available

7-Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)





Chemistry Assessment Section

B. Other Documents:

IND 61757	NAVIDEA BIOPHARMACEUTICALS INC 425 METRO PL NORTH STE 450 DUBLIN, OHIO 43017 UNITED STATES	It is referenced in NDA 202207
-----------	---	--------------------------------

18. STATUS:

ONDC:

ONDC:			
CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	Not consulted by CMC	N/A	N/A
EES	Acceptable	13-Feb-2013	T. Sharp
Pharm/Tox	Approval	26-Jun-2012	Dina A. Olayinka, Ph.D.
Biopharm	Not consulted by CMC	N/A	N/A
LNC	Not consulted by CMC	N/A	N/A
Methods Validation	Will be requested	n/a	n/a
ODS/DMEPA	Properitory name granted.	16-Nov-2011	Jibril Abdus-Samad, PharmD
EA	Claim for categorical	Date of this	Ravindra K. Kasliwal, Ph.D.
	exclusion is acceptable	review.	





(b) (4)

Chemistry Assessment Section

The Chemistry Review for NDA 202207

<u>The Executive Summary</u>

I. Recommendations

A. Recommendation and Conclusion on Approvability

The application is **recommended for approval action** for chemistry, manufacturing and controls (CMC) under section 505 of the Act.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Technetium Tc 99m Tilmanocept binds to receptors on mannose-binding proteins (MBP). Tilmanocept

^{(b) (4)} has a dextran (C-10) backbone conjugated with a linker moiety (an amine terminated "leash") that is subsequently coupled with Diethylenetriamine pentaacetic acid (DTPA) and mannose moieties. The mannose acts as a substrate for the receptor on MBP and the DTPA serves as a chelating agent for radiolabeling with Technetium Tc99m.

Since Tilmanocept has a dextran backbone, it has a molecular weight distribution

carry the amine leash; of those leashes, 3-8 are conjugated to DTPA, 12-20 are conjugated to mannose and 0-17 remain as the free amine. The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454. Tilmanocept is an off-white to buff colored powder that is moderately hygroscopic, very water soluble, and insoluble in alcohol. The pH of a 1% solution of Tilmanocept is \approx 9. Tilmanocept has been observed to degrade only at extreme pH conditions. The degradation is time and temperature dependent (b) (4).

The drug product (trademark: Lymphoseek[®]) will be supplied as "kit" containing a sterile lyophilized preparation of Tilmanocept, 0.25 mg (labeled as Tilmanocept Powder) and co-packaged sterile buffer saline diluent (labeled as DILUENT for Lymphoseek). Tilmanocept Powder vial contains non-radioactive ingredients necessary to produce technetium Tc 99m tilmanocept after radiolabeling with technetium Tc 99m solution obtained from a commercially available generator at the clinical site of use. The Tilmanocept powder vial contains sterile, non-pyrogenic, white to off-white powder, of a mixture of 250 mcg (0.25 mg) of tilmanocept, 20 mg trehalose dihydrate, 0.5 mg glycine, 0.5 mg sodium ascorbate, and 0.075 mg, stannous chloride dihydrate. The contents of the vial are lyophilized and stored under nitrogen. The DILUENT for Lymphoseek contains 4.5 mL sterile buffered saline consisting of 0.04% (w/v) potassium phosphate, 0.11% (w/v) sodium phosphate (heptahydrate), 0.50% (w/v) sodium chloride, and 0.40% (w/v) phenol. The pH is 6.8 - 7.2.

The lyophilized formulation provides $^{(b)(4)}$ lyophilized cake, allowing for quick reconstitution with Sodium Pertechnetate in saline to produce a clear injection solution. Each Tilmanocept powder vial can be radiolabeled with 2.5 - 10 mCi (q.s. 0.35 - 0.7 mL) of sodium pertechnetate solution. The formulation contains $^{(b)(4)}$



Chemistry Assessment Section

(b) (4)



The DILUENT for Lymphoseek should be granted a 2 year expiration dating period at controlled room temperature.

For Tilmanocept powder vial a 12 month tentative expiration dating period may be granted when stored at controlled room temperature, 20°C to 25°C (68°F to 77°F). The applicant will have to confirm this from the first three commercial batches that they manufacture and analyze for potency using the new potency method.

The Kit for the preparation of Lymphoseek (technetium Tc99m tilmanocept) injection should be granted a 12 month expiration dating period.

The radiolabeld Lymphoseek (technetium Tc99m tilmanocept) injection should be granted a 6 hour expiration dating period

B. Description of How the Drug Product is Intended to be Used

Lymphoseek[®] (technetium Tc 99m tilmanocept) injection is indicated for intraoperative localization of tumordraining lymph nodes using a handheld gamma detection probe in patients with breast cancer or melanoma. Prior to administration to the patient, the Nuclear Pharmacy will prepare the injection by taking one lyophilized powder vial and radiolabeling with an amount of radioactivity as Sodium Pertechnetate Tc 99m Injection in isotonic saline. After the prescribed time for the radiolabeling reaction (b)⁽⁴⁾ the vial is brought to the prescribed volume using one of the accompanying diluent, Sterile Buffered Saline. It is then QC tested using Instant Thin Layer Chromatography (ITLC) to ensure that the raiochemcial purity is \geq 90%, and drawn into syringe(s) according to the Physician's order. The Technetium Tc 99m Lymphoseek[®] Injection is typically administered to patients within a few minutes to a few hours following preparation. Because of the short half-life of the radionuclide and the mode of production, the radiolabeled drug product has a shelf life of six (?) hours.

The patient mass dose in every case is 50 µg. The volume, number of injections and amount of radiation will vary depending on the Physician's orders and the type and time of the scheduled surgery. The maximum reconstitution volume is 5.0 mL. Following lymph node mapping protocol is used.

- Use a handheld gamma counter (represented by any FDA-cleared handheld gamma detection probe) to identify
 nodes localizing Technetium Tc 99m Lymphoseek Injection. Measure background counts from tissue at least
 20 centimeters distal to the injection site. Use the background radioactivity counts plus three standard
 deviations from the mean background count level (i.e., the three-sigma rule representing >99.7% probable
 difference from background) as the threshold for positive localization of Technetium Tc 99m Lymphoseek
 Injection.
- All lymphatic mapping agents use elements of the lymphatic system for distribution. The lymph node localization of Technetium Tc 99m Lymphoseek Injection is dependent upon its binding to reticuloendothelial cells within lymph nodes. Based on clinical studies, the localization and degree of localization (ability to detect multiple nodes with potential anatomic nexuses to the tumor bed) of Technetium Tc 99m Lymphoseek Injection is not dependent on the radiopharmaceutical injection technique. The use of Technetium Tc 99m Lymphoseek Injection is intended to complement palpation, visual inspection, and other procedures important to lymph node localization. Intraoperative lymphatic mapping by gamma detection should be initiated no sooner than (b)(4) post-injection and within (b)(4) of administration of Technetium Tc 99m Lymphoseek Injection.





Chemistry Assessment Section

C. Basis for Not-Approval Recommendation

The application is recommended for approval action because of the following:

- 1. Determination that sufficient information is provided in this New Drug Application, as amended, to ensure the identity, strength, quality, and purity of the drug substance.
- Determination that sufficient information is provided in this New Drug Application, as amended, to ensure the identity, strength, quality, and purity of the drug product.
- 3. The referenced drug master files (DMF) are adequate to support the product application.
- 4. The microbiology has recommended approval action from product quality microbiology.
- 5. There are no outstanding issues with specifications, method and impurities.
- The stability of the Tilmanocept powder vial, the DILUENT for Lymphoseek, as well as the radiolabled product has been sufficiently demonstrated to allow for a reasonable expiration dating period (as indicated above)
- The CDER office of Compliance, which had previously recommended withhold from approval action, has now recommended (13-Feb-2013) manufacturing and testing facilities are acceptable.
- 8. The labeling and is found to be acceptable

III. Administrative

A. Reviewer's Signature

Ravindra K Kasliwal, Ph.D.

B. Endorsement Block

Chemist - Name/Date: Ravindra K. Kasliwal/ See DARRTS Chemistry Division-III Director: Eric P. Duffy, Ph.D. / See DARRTS Project Manager - Name/Date: Alberta E. Davis-Warren/ See DARRTS

C. CC Block: See DARRTS

9 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAVINDRA K KASLIWAL 02/19/2013

ERIC P DUFFY 02/26/2013

NDA 202207

Kit for the preparation of Lymphoseek® (technetium Tc 99m tilmanocept) Injection

Summary of the Basis for the Recommended Action from Chemistry, Manufacturing, and Controls

Applicant:	Navidea Biopharmaceuticals, Inc.	
	425 Metro Place North, Suite 300,	
	Dublin, OH 43017	

Indication: Lymphoseek (technetium Tc 99m tilmanocept) Injection is a lymphatic mapping agent indicated for use with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.

Presentation:

The drug product (trademark: Lymphoseek[®]) is supplied as "kit" containing a sterile lyophilized preparation of Tilmanocept, 25 mcg (labeled as Tilmanocept Powder) and copackaged sterile buffer saline diluent (labeled as DILUENT for Lymphoseek). Prior to administration, the Tilmanocept Powder vial is radiolabeled with technetium Tc99m solution at the site of use and then diluted with the supplied diluent.

EER Status:	Recommendations:	Withold recommendation 30-AUG-2021	
	(The office of compliance had withhold recommendation as of 25-Apr		
	2012. This was changed to pending on 09-Aug-2012)		

Consults:	EA-	Categorical exclusion provided
	CDRH-	N/A
	Statistics –	N/A
	Methods Validation –	Will be requested. Package is provided.
	DEMETS-	Completed
	Biopharm–	N/A
	Microbiology –	Approval
	Pharm/toxicology –	Approval

Original Submission:10-Aug-2011Re-submissions:N/A

Post-Approval CMC Commitments:

The applicant commits to provide a statistical analysis of the potency data (for Tilmanocept Powder vial) generated using the new method (SAM3404AR) to determine if the specification can be ^{(b) (4)} of the labeled amount. The evaluation and justification for the potency specification will be provided in the first annual report.

The applicant commits to test for stability the first three production conformance / validation batches according to the post approval stability protocol. Applicant also commits to test for stability not less than one batch produced during each subsequent year of manufacture according to the post approval stability protocol.


The applicant commits to providing the validation report by 31-Dec-2012 for the HPLC impurities method for tilmanocept bulk drug substance.

Background: Drug Substance:

Tilmanocept (DTPA Mannosyl Dextran) is manufactured and tested by (b) (4) . Contract laboratories are used for controlled environmental storage for stability studies, Total Aerobic Microbial Count, Yeasts and Molds testing, heavy metals testing and sodium testing. Tilmanocept drug substance is manufactured

Details of the conjugation processes and controls are provided and have been reviewed.

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT Chemical Names



Technetium-⁹⁹Tc, dextran, 3 [(2aminoethyl) thio]propyl-17-carboxy-10,13,16-tris (carboxymethyl) -8-oxo-4thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio) ethyl] amino] ethyl] thio]propyl ether.

The molecular formula of technetium Tc 99m tilmanocept is $[C_6H_{10}O_5]_n$. (C₁₉H₂₈N₄O₉S^{99m}Tc)_b.(C₁₃H₂₄N₂O₅ S₂)_c.(C₅H₁₁NS)_a; [Where, a = 0-17, b = 12-20, and c = 3-8]

The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454.

In the synthesis of tilmanocept, The information regarding the intermediate is provided in DMF ⁽⁰⁾⁽⁴⁾ The DMF was reviewed and found acceptable. Structural characterization of the drug substance was performed by elelemental analyses, FTIR spectroscopy, ¹H and ¹³C NMR spectroscopy, and laser light scattering for molecular weight. Side by side ¹H and ¹³C NMR spectrum of lot M90612 with and without Technetium ^{99m}Tc radiolabeling was performed for elucidation of structure of the radiolabeled drug substance ^(b) (d)

Tilmanocept has a dextran backbone; it has a molecular weight distribution

carry the amine leash; of those leashes, 3-8 are conjugated to DTPA, 12-20 are conjugated to mannose and 0-17 remain as the free amine. The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454. Tilmanocept is off-white to buff colored powder that is moderately hygroscopic, very water soluble, and insoluble in alcohol. The pH of a 1% solution of Tilmanocept is \approx 9. Tilmanocept has been observed to degrade only at extreme pH conditions. The degradation is time and temperature dependent ^{(b)(4)}

A tilmanocept reference standard was developed as the primary reference standard. The drug substance specifications for impurities were deemed acceptable in consultation with the toxicology reviewer. Tilmanocept specifications include appearance including color, identification, assay, ^{(b)(4)} heavy metals, water content, residual solvents, bacterial endotoxins, total aerobic microbial counts, yeasts and molds, amine number, DTPA number, Mannose number, and molecular weight. Based upon the completed 24 month stability studies, the retest date is ^{(b)(4)} from the time of release. The label includes a retest date and recommended storage conditions of ^{(b)(4)}

Conclusion: The drug substance is satisfactory

Drug Product:

The drug product (trademark: Lymphoseek[®]) is supplied as "kit" containing a sterile lyophilized preparation of Tilmanocept, 0.25 mg (labeled as Tilmanocept Powder) and co-packaged sterile buffer saline diluent (labeled as DILUENT for Lymphoseek). Tilmanocept Powder vial contains non-radioactive ingredients necessary to produce technetium Tc 99m tilmanocept after radiolabeling with technetium Tc 99m solution obtained from a commercially available generator at the clinical site of use. The Tilmanocept powder vial contains sterile, non-pyrogenic, white to off-white powder, of a mixture of 250 mcg (0.25 mg) of tilmanocept, 20 mg trehalose dihydrate, 0.5 mg glycine, 0.5 mg sodium ascorbate, and 0.075 mg, stannous chloride dihydrate. The contents of the vial are lyophilized and stored under nitrogen. The DILUENT for Lymphoseek contains 4.5 mL sterile buffered saline consisting of 0.04% (w/v) potassium phosphate, 0.11% (w/v) sodium phosphate (heptahydrate), 0.50% (w/v) sodium chloride, and 0.40% (w/v) phenol. The pH is 6.8 - 7.2.

The lyophilized formulation provides (b) (4) lyophilized cake, allowing for quick reconstitution with Sodium Pertechnetate in saline to produce a clear injection solution. Each Tilmanocept powder vial can be radiolabeled with 2.5 - 10 mCi (q.s. 0.35 - 0.7 mL) of sodium pertechnetate solution. The formulation contains (b) (4)

The pH of Lymphoseek powder vial is . The diluent is provided to which is considered suitable for parenteral products.

The DILUENT for Lymphoseek has a 2 year expiration dating period at controlled room temperature.

For Tilmanocept powder vial a 12 month tentative expiration dating period may be granted when stored at controlled room temperature, 20°C to 25°C (68°F to 77°F). The applicant will have to confirm this from the first three commercial batches that they manufacture and analyze for potency using the new potency method.

The Kit for the preparation of Lymphoseek (technetium Tc99m tilmanocept) injection should be granted a 12 month expiration dating period.

The radiolabeld Lymphoseek (technetium Tc99m tilmanocept) injection should be granted a 6 hour expiration dating period

Conclusion: The drug product is satisfactory.

Overall Conclusion:

The CMC recommendation is approval as all CMC, including microbiology issues have been satisfactorily addresses. The application, however, may not be approved until an overall cGMP recommendation of acceptable is available.

Eric P. Duffy, Ph.D. Division Director

Reference ID: 3184896

(b) (4)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P DUFFY 09/05/2012

NDA 202207

Kit for the preparation of Lymphoseek[®] (technetium Tc 99m tilmanocept) Injection

Navidea Biopharmaceuticals, Inc. 425 Metro Place North Suite 300 Dublin, OH 43017

Ravindra K. Kasliwal, Ph.D. Division of New Drug Quality Assessment – III Division of Medical Imaging Products





Table of Contents

Ta	ble of Contents	2
Cł	nemistry Review Data Sheet	3
Tł	ne Executive Summary	7
I.	Recommendations	7
	A. Recommendation and Conclusion on Approvability	7
	B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	7
II.	Summary of Chemistry Assessments	7
	A. Description of the Drug Product(s) and Drug Substance(s)	7
	B. Description of How the Drug Product is Intended to be Used	8
	C. Basis for Approvability or Not-Approval Recommendation	9
III.	Administrative	9
	A. Reviewer's Signature	9
	B. Endorsement Block	9
	C. CC Block	9
Cł	nemistry Assessment	10

Chemistry Review Data Sheet

1. NDA 202207

- 2. REVIEW #: 2
- 3. REVIEW DATE: 27-Aug-2012
- 4. REVIEWER: Ravindra K. Kasliwal, Ph.D.

5. PREVIOUS DOCUMENTS:

Submission(s)	Document Date
Original	10-Aug-2011
Amendment	04-Nov-2011
Amendment	06-Jan-2012
Amendment	12-Jan-2012
Amendment	13-Feb-2012
Amendment	17-Feb-2012
Amendment	20-Mar-2012
Amendment	30-Mar-2012
Amendment	05-Apr-2012
Amendment (meeting package)	28-Jun-2012
Amendment	06-Jul-2012

6. SUBMISSION(S) BEING REVIEWED:

S.	Submission	Document Date
1	Amendment	02-Aug-2012

7. NAME & ADDRESS OF APPLICANT:

Name:Navidea Biopharmaceuticals, Inc.Address:425 Metro Place North, Suite 300, Dublin, OH
43017Representative:Rodger Brown, Vice President RA/ QA
Telephone:614-793-7500 x 142

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: Lymphoseek[®]
- b) Non-Proprietary Name (USAN): technetium Tc99m tilmanocept
- c) Code Name/# (ONDC only): 70-2903






Chemistry Assessment Section

- d) Chem. Type/Submission Priority (ONDC only):
 - Chem. Type: 1
 - Submission Priority: S
- 9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)
- 10. PHARMACOL. CATEGORY: Radiopharmaceutical
- 11. DOSAGE FORM: For Injection
- 12. STRENGTH/POTENCY: 250 micrograms
- 13. ROUTE OF ADMINISTRATION: Intradermal
- 14. Rx/OTC DISPENSED: _X_Rx __OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):</u> _____SPOTS product – Form Completed

X Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:



Technetium-⁹⁹Tc, dextran, 3 [(2-aminoethyl) thio]propyl-17-carboxy-10,13,16-tris (carboxymethyl) -8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl] amino] ethyl] thio]propyl ether.

The molecular formula of technetium Tc 99m tilmanocept is $[C_6H_{10}O_5]_{n}$. $(C_{19}H_{28}N_4O_9S^{99m}Tc)_{b}$. $(C_{13}H_{24}N_2O_5S_2)_{c}$. $(C_5H_{11}NS)_{a}$ [Where, a = 0-17, b = 12-20, and c = 3-8]

The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454.





Chemistry Assessment Section

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYP E	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
(b) (4)	Π		(b) (4)	1	Adequate	19-Jul-2012	Reviewed by Ravindra K. Kasliwal, Ph.d. and John Metcalf, Ph.D.
	Ш			4	Adequate	07-Oct-2005	DNF was reviewed for (b) (4) (by Jila Boel, Ph.D.) and was adequate.
	III	*		4	Adequate	06-Aug-2003	DMF was reviewed for a lyophilized powder product (by Ravindra Kasliwal, Ph.D.) and was adequate.
	V	- -		4	N/A	N/A	The DMF describes ^{(b) (4)} and is reviewed by product quality microbiology.
	Π			1	Adequate	18-Jul-2012	Reviewed by Ravindra K. Kasliwal, Ph.D.
	III			3, 4	N/A	N/A	The stopper is used in diluent vial. The stopper is used in many injectable products.

¹Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2-Type 1 DMF

3 - Reviewed previously and no revision since last review

4 - Sufficient information in application

5 - Authority to reference not granted

6 – DMF not available


7 - Other (explain under "Comments")

²Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

	NAVIDEA BIOPHARMACEUTICALS INC	
IND 61757	425 METRO PL NORTH STE 450	It is referenced in NDA 202207
	DUBLIN, OHIO 43017	





UNITED STATES

18. STATUS:

ONDC:

UNDC.			1
CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	Not consulted by CMC	N/A	N/A
EES	Pending	09-Aug-2012 (still same as of the date of this review)	Office of compliance had withhold recommendation as of 25-Apr-2012. This was changed to pending, in view if the changes to the testing methods and facility made by the applicant.
Pharm/Tox	Approval	26-Jun-2012	Dina A. Olayinka, Ph.D.
Biopharm	Not consulted by CMC	N/A	N/A
LNC	Not consulted by CMC	N/A	N/A
Methods Validation	Will be requested	n/a	The package will need to be updated with product specifications and analytical methods and validation data.
ODS/DMEPA	Properitory name granted.	16-Nov-2011	Jibril Abdus-Samad, PharmD
EA	Claim for categorical exclusion is acceptable	Date of this review.	Ravindra K. Kasliwal, Ph.D.





Chemistry Assessment Section

The Chemistry Review for NDA 202207

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

The application is **recommended for approval** for chemistry, manufacturing and controls (CMC) under section 505 of the Act, provided the manufacturing and testing facilities are found to be acceptable by the office of compliance and labeling is found to be acceptable. The office of compliance had withhold recommendation as of 25-Apr-2012. This was changed to pending (09-Aug-2012), in view if the changes to the testing methods and facility made by the applicant.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)


Technetium Tc 99m Tilmanocept binds to receptors on mannose-binding proteins (MBP). Tilmanocept

^{(b) (4)} has a dextran (C-10) backbone conjugated with a linker moiety (an amine terminated "leash") that is subsequently coupled with Diethylenetriamine pentaacetic acid (DTPA) and mannose moieties. The mannose acts as a substrate for the receptor on MBP and the DTPA serves as a chelating agent for radiolabeling with Technetium Tc99m.

Since Tilmanocept has a dextran backbone, it has a molecular weight distribution (b) (4)

carry the amine leash; of those leashes, 3-8 are conjugated to DTPA, 12-20 are conjugated to mannose and 0-17 remain as the free amine. The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454. Tilmanocept is an off-white to buff colored powder that is moderately hygroscopic, very water soluble, and insoluble in alcohol. The pH of a 1% solution of Tilmanocept is \approx 9. Tilmanocept has been observed to degrade only at extreme pH conditions. The degradation is time and temperature dependent.

The drug product (trademark: Lymphoseek[®]) will be supplied as "kit" containing a sterile lyophilized preparation of Tilmanocept, 0.25 mg (labeled as Tilmanocept Powder) and co-packaged sterile buffer saline diluent (labeled as DILUENT for Lymphoseek). Tilmanocept Powder vial contains non-radioactive ingredients necessary to produce technetium Tc 99m tilmanocept after radiolabeling with technetium Tc 99m solution obtained from a commercially available generator at the clinical site of use. The Tilmanocept powder vial contains sterile, non-pyrogenic, white to off-white powder, of a mixture of 250 mcg (0.25 mg) of tilmanocept, 20 mg trehalose dihydrate, 0.5 mg glycine, 0.5 mg sodium ascorbate, and 0.075 mg, stannous chloride dihydrate. The contents of the vial are lyophilized and stored under nitrogen. The DILUENT for Lymphoseek contains 4.5 mL sterile buffered saline consisting of 0.04% (w/v) potassium phosphate, 0.11% (w/v) sodium phosphate (heptahydrate), 0.50% (w/v) sodium chloride, and 0.40% (w/v) phenol. The pH is 6.8 - 7.2.





The lyophilized formulation provides ^{(b) (4)} lyophilized cake, allowing for quick reconstitution with Sodium Pertechnetate in saline to produce a clear injection solution. Each Tilmanocept powder vial can be radiolabeled with 2.5 – 10 mCi (q.s. 0.35 – 0.7 mL) of sodium pertechnetate solution. The formulation contains ^{(b) (4)}

The pH of Lymphoseek powder vial is diluent is provided to parenteral products.

^{(b) (4)}. The ^{(b) (4)} which is considered suitable for

The DILUENT for Lymphoseek should be granted a 2 year expiration dating period at controlled room temperature.

For Tilmanocept powder vial a 12 month tentative expiration dating period may be granted when stored at controlled room temperature, 20°C to 25°C (68°F to 77°F). The applicant will have to confirm this from the first three commercial batches that they manufacture and analyze for potency using the new potency method.

The Kit for the preparation of Lymphoseek (technetium Tc99m tilmanocept) injection should be granted a 12 month expiration dating period.

The radiolabeld Lymphoseek (technetium Tc99m tilmanocept) injection should be granted a 6 hour expiration dating period


B. Description of How the Drug Product is Intended to be Used

Lymphoseek[®] (technetium Tc 99m tilmanocept) injection is indicated for intraoperative localization of tumordraining lymph nodes using a handheld gamma detection probe in patients with breast cancer or melanoma. Prior to administration to the patient, the Nuclear Pharmacy will prepare the injection by taking one lyophilized powder vial and radiolabeling with an amount of radioactivity as Sodium Pertechnetate Tc 99m Injection in isotonic saline. After the prescribed time for the radiolabeling reaction (b) (4) the vial is brought to the prescribed volume using one of the accompanying diluent, Sterile Buffered Saline. It is then QC tested using Instant Thin Layer Chromatography (ITLC) to ensure that the raiochemcial purity is \geq 90%, and drawn into syringe(s) according to the Physician's order. The Technetium Tc 99m Lymphoseek[®] Injection is typically administered to patients within a few minutes to a few hours following preparation. Because of the short half-life of the radionuclide and the mode of production, the radiolabeled drug product has a shelf life of six (?) hours.

The patient mass dose in every case is 50 µg. The volume, number of injections and amount of radiation will vary depending on the Physician's orders and the type and time of the scheduled surgery. The maximum reconstitution volume is 5.0 mL. Following lymph node mapping protocol is used.

- Use a handheld gamma counter (represented by any FDA-cleared handheld gamma detection probe) to identify
 nodes localizing Technetium Tc 99m Lymphoseek Injection. Measure background counts from tissue at least
 20 centimeters distal to the injection site. Use the background radioactivity counts plus three standard
 deviations from the mean background count level (i.e., the three-sigma rule representing >99.7% probable
 difference from background) as the threshold for positive localization of Technetium Tc 99m Lymphoseek
 Injection.
- All lymphatic mapping agents use elements of the lymphatic system for distribution. The lymph node localization of Technetium Tc 99m Lymphoseek Injection is dependent upon its binding to reticuloendothelial cells within lymph nodes. Based on clinical studies, the localization and degree of localization (ability to detect multiple nodes with potential anatomic nexuses to the tumor bed) of Technetium Tc 99m Lymphoseek





Injection is not dependent on the radiopharmaceutical injection technique. The use of Technetium Tc 99m Lymphoseek Injection is intended to complement palpation, visual inspection, and other procedures important to lymph node localization. Intraoperative lymphatic mapping by gamma detection should be initiated no sooner than _________ post-injection and within _________ of administration of Technetium Tc 99m Lymphoseek Injection.

C. Basis for Not-Approval Recommendation

The application is recommended for approval, provided the manufacturing and testing facilities are found to be acceptable by the office of compliance and labeling is found to be acceptable, because of the following:

- 1. Determination that sufficient information is provided in this New Drug Application, as amended, to ensure the identity, strength, quality, and purity of the drug substance.
- 2. Determination that sufficient information is provided in this New Drug Application, as amended, to ensure the identity, strength, quality, and purity of the drug product.
- 3. The referenced drug master files (DMF) are adequate to support the product application.
- 4. The microbiology has recommended approval action from product quality microbiology.
- 5. There are no outstanding issues with specifications, method and impurities.
- The stability of the Tilmanocept powder vial, the DILUENT for Lymphoseek, as well as the radiolabled product has been sufficiently demonstrated to allow for a reasonable expiration dating period (as indicated above)

III. Administrative

A. Reviewer's Signature

Ravindra K Kasliwal, Ph.D.

B. Endorsement Block

Chemist - Name/Date: Ravindra K. Kasliwal/ See DARRTS Chemistry Branch Chief - Name/Date: Ali Al-Hakim, Ph.D./ See DARRTS Project Manager - Name/Date: Alberta E. Davis-Warren/ See DARRTS

C. CC Block: See DARRTS

17 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAVINDRA K KASLIWAL 08/26/2012

ERIC P DUFFY 08/27/2012

NDA 202207

Lymphoseek®

Kit for the preparation of technetium Tc 99m tilmanocept injection

Navidea Biopharmaceuticals, Inc. 425 Metro Place North Suite 300 Dublin, OH 43017

Ravindra K. Kasliwal, Ph.D. Division of New Drug Quality Assessment – III Division of Medical Imaging Products





Table of Contents

T٤	ble of Contents2
Cl	nemistry Review Data Sheet3
T	ne Executive Summary7
I.	Recommendations
	A. Recommendation and Conclusion on Approvability7
	B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
II.	Summary of Chemistry Assessments
	A. Description of the Drug Product(s) and Drug Substance(s)
	B. Description of How the Drug Product is Intended to be Used
	C. Basis for Approvability or Not-Approval Recommendation
III	Administrative
	A. Reviewer's Signature
	B. Endorsement Block
	C. CC Block
Cl	nemistry Assessment10
I.	Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data10
	S DRUG SUBSTANCE [Name, Manufacturer]
	P DRUG PRODUCT [Name, Dosage form]
	A APPENDICES
	R REGIONAL INFORMATION
II.	Review Of Common Technical Document-Quality (Ctd-Q) Module 1
	A. Labeling & Package Insert
	B. Environmental Assessment Or Claim Of Categorical Exclusion
III	List Of Deficiencies To Be Communicated

Chemistry Review Data Sheet

1. NDA 202207

- 2. REVIEW #: 1
- 3. REVIEW DATE: 19-Jul-2012
- 4. REVIEWER: Ravindra K. Kasliwal, Ph.D.

5. PREVIOUS DOCUMENTS: None

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed	Document Date
Original	10-Aug-2011
Amendment	04-Nov-2011
Amendment	06-Jan-2012
Amendment	12-Jan-2012
Amendment	13-Feb-2012
Amendment	17-Feb-2012
Amendment	20-Mar-2012
Amendment	30-Mar-2012
Amendment	05-Apr-2012
Amendment (meeting package)	28-Jun-2012
Amendment	06-Jul-2012


7. NAME & ADDRESS OF APPLICANT:

Name:	Navidea Biopharmaceuticals, Inc.
Address:	425 Metro Place North, Suite 300, Dublin, OH 43017
Representative:	Rodger Brown, Vice President RA/ QA
Telephone:	614-793-7500 x 142

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: Lymphoseek[®]
- b) Non-Proprietary Name (USAN): technetium Tc99m tilmanocept
- c) Code Name/# (ONDC only): 70-2903
- d) Chem. Type/Submission Priority (ONDC only):
 - Chem. Type: 1
 - Submission Priority: S






- 9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)
- 10. PHARMACOL. CATEGORY: Radiopharmaceutical
- 11. DOSAGE FORM: For Injection
- 12. STRENGTH/POTENCY: 250 micrograms
- 13. ROUTE OF ADMINISTRATION: Intradermal
- 14. Rx/OTC DISPENSED: _X_Rx __OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):</u> ______SPOTS product – Form Completed

X Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:



Technetium-⁹⁹Tc, dextran, 3 [(2-aminoethyl) thio]propyl-17-carboxy-10,13,16-tris (carboxymethyl) -8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl] amino] ethyl] thio]propyl ether.

The molecular formula of technetium Tc 99m tilmanocept is $[C_6H_{10}O_5]_n.(C_{19}H_{28}N_4O_9S^{99m}Tc)_b.(C_{13}H_{24}N_2O_5S_2)_c.(C_5H_{11}NS)_a$ [Where, a = 0-17, b = 12-20, and c = 3-8]

The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454.

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:





DMF #	TYP E	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
(b) (4	II		(b) (4)	1	Adequate	19-Jul-2012	Reviewed by Ravindra K. Kasliwal, Ph.d. and John Metcalf, Ph.D.
	Ш			4	Adequate	07-Oct-2005	DNF was reviewed for ^{(b) (4)} (by Jila Boel, Ph.D.) and was adequate.
	Ш			4	Adequate	06-Aug-2003	DMF was reviewed for a lyophilized powder product (by Ravindra Kasliwal, Ph.D.) and was adequate.
	V			4	N/A	N/A	The DMF describes ^{(b) (4)} and is reviewed by product quality microbiology.
	Π			1	Adequate	18-Jul-2012	Reviewed by Ravindra K. Kasliwal, Ph.D.
	III			3, 4	N/A	N/A	The stopper is used in diluent vial. The stopper is used in many injectable products.

Chemistry Assessment Section

¹Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2-Type 1 DMF

3 - Reviewed previously and no revision since last review

 $4-Sufficient\ information\ in\ application$

5 - Authority to reference not granted

6 – DMF not available

7-Other (explain under "Comments")

²Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

IND 61757	NAVIDEA BIOPHARMACEUTICALS INC 425 METRO PL NORTH STE 450 DUBLIN, OHIO 43017 UNITED STATES	It is referenced in NDA 202207
-----------	---	--------------------------------





Chemistry Assessment Section

18. STATUS:

ONDC:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	Not consulted by CMC	N/A	N/A
EES	Withhold	25-Apr-2012	Office of compliance.
Pharm/Tox	Approval	26-Jun-2012	Dina A. Olayinka, Ph.D.
Biopharm	Not consulted by CMC	N/A	N/A
LNC	Not consulted by CMC	N/A	N/A
Methods Validation	Will be requested	n/a	The package will need to be updated with product specifications and analytical methods and validation data.
ODS/DMEPA	Properitory name granted.	16-Nov-2011	Jibril Abdus-Samad, PharmD
EA	Claim for categorical exclusion is acceptable	Date of this review.	Ravindra K. Kasliwal, Ph.D.





Chemistry Assessment Section

The Chemistry Review for NDA 202207

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

The application is **not approval** for chemistry, manufacturing and controls (CMC) under section 505 of the Act. The reasons for not approval are CMC deficiencies (listed at the end of review) and withhold recommendation on manufacturing facilities from the Office of Compliance.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

- Recommend that the company provide a phase 4 commitment to provide 12 month long term and 6 month accelerated stability data and analysis using the new methods and updated specifications on first three production, conformance or commercial lots (reflective of commercial manufacturer). These lots should be manufactured using different lots of Tilmanocept drug substance. This commitment should be completed within 15 months of approval of this drug product.
- Recommend that the company provide a phase 4 commitment to develop a method to quantitate ^(b)
 (4)
 in Lymphoseek powder vial and radiolabled drug product as part of the drug product release and
 stability testing program. This should be completed within 12 months of approval of this drug product.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Technetium Tc 99m Tilmanocept binds to receptors on mannose-binding proteins (MBP). Tilmanocept

^{(b) (4)} has a dextran (C-10) backbone conjugated with a linker moiety (an amine terminated "leash") that is subsequently coupled with Diethylenetriamine pentaacetic acid (DTPA) and mannose moieties. The mannose acts as a substrate for the receptor on MBP and the DTPA serves as a chelating agent for radiolabeling with Technetium Tc99m.

Since Tilmanocept has a dextran backbone, it has a molecular weight distribution (b) (4)

carry the amine leash; of those leashes, 3-8 are conjugated to DTPA, 12-20 are conjugated to mannose and 0-17 remain as the free amine. The calculated average molecular weight of tilmanocept will range from 15,281 to 23,454. Tilmanocept is an off-white to buff colored powder that is moderately hygroscopic, very water soluble, and insoluble in alcohol. The pH of a 1% solution of Tilmanocept is \approx 9. Tilmanocept has been observed to degrade only at extreme pH conditions. The degradation is time and temperature dependent.

The drug product (trademark: Lymphoseek[®]) will be supplied as "kit" containing a sterile lyophilized preparation of Tilmanocept, 0.25 mg (labeled as Tilmanocept Powder for Injection) and co-packaged sterile buffer saline diluent (labeled as DILUENT for Lymphoseek). Tilmanocept Powder vial contains non-radioactive ingredients necessary to produce technetium Tc 99m tilmanocept after radiolabeling with technetium Tc 99m solution obtained from a commercially available generator at the clinical site of use. The Tilmanocept powder vial contains sterile, non-pyrogenic, white to off-white powder, of a mixture of 250 mcg (0.25 mg) of tilmanocept, 20 mg trehalose dihydrate, 0.5 mg glycine, 0.5 mg sodium ascorbate, and 0.075 mg, stannous chloride dihydrate. The contents of the vial are



Chemistry Assessment Section

lyophilized and stored under nitrogen. The DILUENT for Lymphoseek contains 4.5 mL sterile buffered saline consisting of 0.04% (w/v) potassium phosphate, 0.11% (w/v) sodium phosphate (heptahydrate), 0.50% (w/v) sodium chloride, and 0.40% (w/v) phenol. The pH is 6.8 - 7.2.

The lyophilized formulation provides $^{(b)(4)}$ lyophilized cake, allowing for quick reconstitution with Sodium Pertechnetate in saline to produce a clear injection solution. Each Tilmanocept powder vial can be radiolabeled with 2.5 - 10 mCi (q.s. 0.35 - 0.7 mL) of sodium pertechnetate solution. The formulation contains $^{(b)(4)}$



The pH of Lymphoseek powder vial is diluent is provided to parenteral products.

^{(b) (4)} which is considered suitable for

B. Description of How the Drug Product is Intended to be Used

Lymphoseek[®] (technetium Tc 99m tilmanocept) injection is indicated for intraoperative localization of tumordraining lymph nodes using a handheld gamma detection probe in patients with breast cancer or melanoma. Prior to administration to the patient, the Nuclear Pharmacy will prepare the injection by taking one lyophilized powder vial and radiolabeling with an amount of radioactivity as Sodium Pertechnetate Tc 99m Injection in isotonic saline. After the prescribed time for the radiolabeling reaction ($^{(b)(4)}$ the vial is brought to the prescribed volume using one of the accompanying diluent, Sterile Buffered Saline. It is then QC tested using Instant Thin Layer Chromatography (ITLC) to ensure that the raiochemcial purity is \geq 90%, and drawn into syringe(s) according to the Physician's order. The Technetium Tc 99m Lymphoseek[®] Injection is typically administered to patients within a few minutes to a few hours following preparation. Because of the short half-life of the radionuclide and the mode of production, the radiolabeled drug product has a shelf life of six (?) hours.

The patient mass dose in every case is 50 µg. The volume, number of injections and amount of radiation will vary depending on the Physician's orders and the type and time of the scheduled surgery. The maximum reconstitution volume is 5.0 mL. Following lymph node mapping protocol is used.

- Use a handheld gamma counter (represented by any FDA-cleared handheld gamma detection probe) to identify
 nodes localizing Technetium Tc 99m Lymphoseek Injection. Measure background counts from tissue at least
 20 centimeters distal to the injection site. Use the background radioactivity counts plus three standard
 deviations from the mean background count level (i.e., the three-sigma rule representing >99.7% probable
 difference from background) as the threshold for positive localization of Technetium Tc 99m Lymphoseek
 Injection.
- All lymphatic mapping agents use elements of the lymphatic system for distribution. The lymph node localization of Technetium Tc 99m Lymphoseek Injection is dependent upon its binding to reticuloendothelial cells within lymph nodes. Based on clinical studies, the localization and degree of localization (ability to detect multiple nodes with potential anatomic nexuses to the tumor bed) of Technetium Tc 99m Lymphoseek Injection is not dependent on the radiopharmaceutical injection technique. The use of Technetium Tc 99m Lymphoseek Injection is intended to complement palpation, visual inspection, and other procedures important to lymph node localization. Intraoperative lymphatic mapping by gamma detection should be initiated no sooner than (b)(4) post-injection and within (b)(4) of administration of Technetium Tc 99m Lymphoseek Injection.

C. Basis for Not-Approval Recommendation

The application is not approval because of the following issues:





Chemistry Assessment Section

- The analytical method ^{(b) (4)} used for the identification and quantitation (assay) of Tilmancept in Lymphoseek drug product is not suitable for the quantitation of tilmancept in Lymphoseek drug product. In the method the ^{(b) (4)} and therefore the assay (potency) results are not reliable. Therefore, the potency data in the NDA (release and stability) can not be relied upon.
- The supplied in-use radiolabeled product data do not support the proposed 6 hour shelf life for the radiolabeled product.
- 3. The Office of Compliance (see EES report dated 25-Apr-2012) has recommended withhold from approval for the manufacturing facilities. The basis for their recommendation is:
 - a. Multiple significant CGMP deficiencies in (b) (4) manufactures and tests the Tilmanocept drug substance and will be performing these activities for the commercial product as well. The site currently has withhold recommendation.
 - b. CGMP deficiencies in the facilities of (b) (4) manufactures (lyophilized sterile fill product) the finished drug product for Navidea and will manufacture the commercial product as well. The site currently has withhold recommendation.
 - c. cGMP and potency method performance deficiencies in (b) (4) has developed the analytical methods and conducts release and stability testing on finished drug product. (b) (4) will perform these activities for the commercial product as well. The site currently has withhold recommendation.

Additionally, issues arising from a change in the potency method are listed under "Deficiencies to be communicated" at the end of this review. These will also need to be satisfactorily addressed prior to any approval action.

III. Administrative

A. Reviewer's Signature

Ravindra K Kasliwal, Ph.D.

B. Endorsement Block

Chemist - Name/Date: Ravindra K. Kasliwal/ See DARRTS Chemistry Branch Chief - Name/Date: Ali Al-Hakim, Ph.D./ See DARRTS Project Manager - Name/Date: Alberta E. Davis-Warren/ See DARRTS

C. CC Block: See DARRTS

128 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAVINDRA K KASLIWAL 07/19/2012

ERIC P DUFFY 07/19/2012

Initial Quality Assessment (IQA) For Division of New Drug Quality Assessment III, Branch VII Office of New Drug Quality Assessment

OND Division: DMIP NDA: 202207 Applicant: Neoprobe Corporation 425 Metro Place North, Suite 300 Dublin, Ohio 43017 (Responsible Official: Rodger Brown, Vice President, RA/QA; phone 614-793-7500, # 142)

PDUFA: TBD Trademark: Lymphoseek Established: Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection Dosage Form: Sterile solution Route of Administration: Intradermal, subcutaneous, subareolar, or peritumoral injection Indication:

CMC Lead: Eldon E. Leutzinger, Ph.D.

ONDQA Fileability YES (X) NO

Comments for 74-Day Letter: None at this time - will await review by primary reviewer

Summary and Critical Issues:

A. <u>Summary</u>

DRUG PRODUCT

Lymphoseek is a lyophilized vial ("cold" kit) that after radiolabeling with Sodium Pertechnetate Tc 99m Injection produces Technetium Tc 99m Tilmanocept (see review section for Drug Substance). **Each "cold" kit (pharmacy package) consists of**:

5 Single-use lyophilized vials of powder (Tilmanocept + (b) (4) + excipients) Composition (Section 3.2.P.1.2) - see Table 1, review page 2

5 Vials of diluent (Sterile Buffered Saline) Composition (Section 3.2.P.1.4) – see Table 2, review page 3

The lyophilized vial containing Tilmanocept is supplied in a	(b) (4)
Vial (USP/Ph.Eur., certified Type 1 glass) with	1 a ^{(b) (4)}
Stopper (b) (4)	
USP/Ph.Eur certified. The stopper is sealed to the vial with	1)
The composition of the lyophilized vials is	s shown
as follows, reproduced from Section 3.2.P.1.2.	

Component	Amount per vial (mg)	Function	Quality Standard
Tilmanocept	0.25	Drug Substance	Company Standard
Glycine	0.5	(b) (4)	USP, Ph. Eur.
Sodium Ascorbate	0.5	-	USP, Ph. Eur.
Trehalose, Dihydrate	20	_	NF
Stannous Chloride, Dihydrate	0.075	_	NF, Ph. Eur.
(b) (4)	(b) (4)	-	NF, Ph. Eur.
-	• • •	-	NF, Ph. Eur.
Nitrogen		-	NF, Ph. Eur.
Water For Injection	*	-	USP, Ph. Eur.

Table 1. Lymphoseek[®] (Tilmanocept) 0.25 mg (Lyophilized Vial)

Tilmanocept has the following chemical structure:




Figure 1. Tilmanocept Structural Formula (Relative Stereochemistry)

Its chemical name is Dextran, 3[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec—1yl-3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether. A shorter name is provided by the applicant as "diethylenetriaminepentaacetic acid mannosyl dextran," or

During radiolabeling, the DTPA end in the chain (Figure 1) complexes wit

Component

From the package insert, radiolabeling

They say that each lot of diluent will be released by Neoprobe or their to the DMF. ^{(b) (4)} based on the contract manufacturer ^{(b) (4)} prior to co-packaging with Lymphoseek. The diluent to release COA provided by be co-packaged with Lymphoseek is the same as was used in the Phase 2 and Phase 3 clinical studies - supplier also the same. The composition of the diluent is as follows, as reproduced from Section 3.2.P.1.4:

Components and Composition Buffered Saline

Amount per unit

(%)

0.04

0.11

0.5

0.4

The **diluent (Sterile Buffered Saline)** is contained in a glass vial, (b) (4) and has a DMF (b) (4) a letter of authorization is provided for access

just DTPA Mannosyl Dextran (= Lymphoseek Ligand), CAS RN 1185986-76-8. Tilmanocept is an off-white to buff-colored powder. It is very soluble in water, but insoluble in alcohol. Tilmanocept is moderately hygroscopic. Nothing is known about polymorphism, since it has not been so investigated. It possesses 5 asymmetric centers

Reference ID: 3009600

Table 2.

Phenol

Potassium Phosphate

Sodium Chloride

Sodium Phosphate ·7H2O

(b) (4)

Function

(b) (4

(b) (4)

consists of adding 2.5 - 10 mCi of ^{(b) (4)} Sodium Pertechnetate Tc 99m Injection in approximately 0.35 to 0.70 mL to a Lymphoseek lyophilized vial, gently swirled and allowed to stand for ^{(b) (4)} Diluent is next added to bring the volume contents to 5.0 mL. The vial is then assayed and checked for radiochemical purity.

COMMENTS:

Because the Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection is a "cold" kit, i.e., it requires reconstitution (radiolabeling) with Sodium Pertechnetate Tc 99m Injection before it can be used for patient administration. So, there is effectively two drug products, one prior to radiolabeling ("cold kit") and one following radiolabeling ("radiolabeled kit"). Since the latter pertains to the Drug Substance, further discussion of this point is delayed until the next section on Drug Product. However, the recognition of this nuance for radiopharmaceutical kits is important, since it bears on what should be and what does not need to be inspected for CGMP's.

Drug Product (finished "cold" kit) is manufactured by product inspection, AQL testing, packaging and labeling by the same firm, but at facility with address of

The manufacture of the Kit for Preparation of Technetium Tc 99m Tilmanocept for Injection essentially follows what is typical for any other radiopharmaceutical kit, the most critical element of which is establishing conditions in the kit

A flow diagram occurs at the end of this section (3.2.P.3.3.10). I have examined these sections and have no initial comments, and am leaving this to a more detailed review by the primary reviewer.

There are specifications for release of manufactured Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection, found in Table 1 (Section 3.2.P.5.1), for the Diluent (Buffered Saline) in Table 2 (same section). On a cursory examination, I have not found anything that jumped out at me, and am leaving these specifications for more detailed review by the primary reviewer.

Stability:

There is a reasonably good summary of the stability studies, batches in the study and data in Section 3.2.P.8.3. There is a lot of information provided in this section, and I do not intend to make any detailed discussion of it within this initial review (IQA). They have provided data for 3 primary batches of the Kit for Preparation of Tchnetium Tc 99m Tilmanocept for Injection (Lymphoseek) in the container closure system intended for

marketing

12 months for Lot NMK001, 18 months for Lot NMK002, 12 months for Lot NMK003 at 25^{0} C/60%RH, where the testing at initial and 3 months is at and 6 months / beyond is at ^{(b) (4)} There are data for all 3 of these batches for 6 months at 40^{0} C/75% RH – some of the testing is done at ^{(b) (4)}. There are some other data that I will not discuss here. Tests and stability specifications are described in this section. I have not examined this body of stability data in great detail, but I have not seen anything too serious in its initial review (IQA); I am leaving this up to the primary reviewer, but the necessary body of data appears to be in place for filing of the NDA.

DRUG SUBSTANCE

During the radiolabeling reaction, all 5 of the carboxylic groups and the 3 nitrogen atoms in the DTPA backbone coordinate with 99m Tc(IV) to form the following complex (Drug Substance):





Figure 2. Possible Structure of Technetium Tc 99m-DTPA Complex

(b) (4)

(b) (4)



for the complex as <u>Critical Issue #8</u>. But, understand, although I am identifying it as such, it is not possess the same level of criticality as the other Critical Issues (later in this review).

Now, reference to the above complex, we are talking about two different entities. The first of these is Tilmanocept, the ligand that binds to 99m Tc(IV). Since this ligand is also a compound in the following sequence, it is an immediate "precursor" to the above complex. There is no drug substance guidance at this moment. For Drug Substance, we can go to the regulations. For a definition of Final Intermediate, we must go to the following guidance:

[Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances, February 1987]

This guidance also contains a definition of Drug Substance, which is essentially that defined in the regulations. Tilmanocept (ligand, precursor) is a <u>final intermediate</u>, as inferred from the definition in the above indicated guidance - the "last compound synthesized before the reaction [radiolabeling] that produces the new drug substance." But, the Drug Substance is the above complex (^{99m}Tc-labeled Tilmanocept), or "active moiety," by 21 CFR 314.108(a). This is the entity that accounts for the biodistribution of radioactivity following administration of the radiolabeled kit. However, the Kit for Preparation of Technetium Tc 99m Tilmanocept for Injection is considered a finished pharmaceutical in of itself, and will be stored in the nuclear pharmacy (as any other pharmaceutical) until needed. Also, note that the NDA refers to ⁽⁰⁾⁽⁴⁾ as the drug substance manufacturer (so, we are well set-up to request inspection of this site).

The manufacturer of Tilmanocept is

(b) (4)

Tilmanocept. This will again be discussed under Critical Issues. There are specifications for Tilmanocept, and these are presented in their Table 1 (Section 3.2.S.4.1). I am going to leave most of this to the primary reviewer, but will mention one or two items in the specifications that might need some additional examination (see Critical Issues).

Stability (Tilmanocept):

They have 3 primary stability batches (commercial scale;

(b) (4)

(b) (4)

7

), packaged in HDPE bottles, with 24 months of data at 25 C \pm 2 C and 60 \pm 5% relative humidity, and 6 months of data at 40^oC \pm 2^oC and 75 \pm 5% relative humidity (Section 3.2.S.7.3, as well as 3.2.S.7.1). There are also data for 2 validation batches included in the section. I have not seen anything particularly concerning, based on a very cursory examination of this data. It, of course, must be examined in greater detail, and this I am leaving up to the primary reviewer.

B. Critical Issues for Review

Filing Summary:	Summar	y:
-----------------	--------	----

	Parameter	Yes	No	Comment
1	On its face, is the section organized adequately?	Х		
2	Is the section indexed and paginated adequately?	Х		
3	On its face, is the section legible?	Х		
4	Are ALL of the facilities (including contract			
	facilities and test laboratories) identified with full street addresses and CFNs?	X		
5	Is a statement provided that all facilities are ready for GMP inspection?	Х		All sites for manufacture of Lymphoseek & Tilmanocept (Section 3.2.P.3.1.1).
6	Has an environmental assessment report or categorical exclusion been provided?	X		
7	Does the section contain controls for the drug substance?	X		
8	Does the section contain controls for the drug product?	X		
9	Has stability data and analysis been provided to support the requested expiration date?	Х		
10	Has all information requested during the IND phase, and at the pre-NDA meetings been included?	х		To my knowledge, based on the listed correspondence provided in the NDA.
11	Have draft container labels been provided?	Х		
12	Has the draft package insert been provided?	Х		All labels.
13	Has an investigational formulations section been provided?	X		
14	Is there a Methods Validation package?	X		As qualified – within the section for analytical methods
15	Is a separate Microbiological section included?	Х		As qualified – enclosed within the manufacturing section
16	Have all consults been identified and initiated?	x		Actually, not a consult, but rather an independent review assignment. John Metcalf is the assigned microbiology reviewer.

COMMENTS:

All the sites for manufacture of Lymphoseek are indicated to be ready for inspection (Section 3.2 P.3.1.1), as indicated in the above table.

Manufacturers:

In the following tables (from Form 356) are listed the facilities for manufacture of Tilmanocept and product (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection), and the several analytical testing laboratories. See the next review page.

356h Attachment - H	Establishment	Information
---------------------	---------------	-------------

Role	Company	Address	FDA Registration Number	FEI Number	Responsibility	Name of Contact Person	Telephone No.
NDA Sponsor	Neoprobe Corporation Inc	425 Metro Place North Suite 300 Dublin, OH 43017			Quality Assurance of the drug product, release of the drug product to clinical studies.	Rodger Brown	(614) 822-2342
API Manufacturer							(b) (4
API Laboratory Contractor							
API Laboratory Contractor							
Product Laboratory Contractor							

Page 1 of 3

Role	Сотрапу	Address	FDA Registration Number	FEI Number	Responsibility	Name of Contact Person	Telephone No.
Product Laboratory Contractor							(b
Product Laboratory Contractor							
Product Laboratory Contractor							
Product Laboratory Contractor							

356h Attachment - Establishment Information

Role	Company	Address	FDA Registration Number	FE1 Number	Responsibility	Name of Contact Person	Telephone No.
Production Site							(b) (4)

356h Attachment - Establishment Information

COMMENTS:

Information on the manufacturers appears to be complete.

<u>Drug Master Files</u> There are no DMF's described in the application.

DMF Number	Holder	Description	LOA Included	Status
		(b) (4)	Yes	
			Yes	
			Yes	
			Yes	
			Yes	

(b) (4) But, also note in the list of * Their LOA refers to ⁽⁰⁾⁽⁴⁾ is listed as the active ingredient manufacturer. As far establishment information as I know, each of these DMF's (unless it would be, e.g., (b) (4)) will need to be reviewed in relation to this NDA.

Labeling:

As indicated in the Filing Summary, there is draft labeling (not only for the package insert, but also for vials and cartons). I am leaving these to the primary reviewer to address.

CMC Lead: Eldon E. Leutzinger, Ph.D. Date: 09/01/2011 Division of New Drug Quality Assessment III, Branch VII

Branch Chief: Ali Al Hakim, Ph.D. Division of New Drug Quality Assessment III, Branch VII

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELDON E LEUTZINGER 09/01/2011

ALI H AL HAKIM 09/01/2011

Ar "nation:	NDA 202207/00	0		Spor	sor:	NAVIDEA BIOPHARMS
C ade:	160					425 METRO PL NORTH STE 450
Priority:	1					DUBLIN, OH 430171367
Stamp Date:	10-AUG-2011			Bran	d Name:	LYMPHOSEEK
PDUFA Date:	30-APR-2013			Esta	b. Name:	
Action Goal:				Gene	ric Name:	Tilmanocept
District Goal:	01-MAR-2013			Prod	uct Number; D	losage Form; Ingredient; Strengths
					001; POWDER,	FOR INJECTION SOLUTION; TILMANOCEPT; .25MG
FDA Contacts:	Y. LIU		Proj	ect Manager		3017961926
	R. KASLIWAL		Rev	iew Chemist		3017961386
	E. LEUTZINGE	R	Tea	m Leader		3017961399
	<u> </u>	,,				
Overall Recommend	ation:	ACCEPTABLE		on 13-FEB-201	by T. SHARI	P () 3017963208
		PENDING		on 12-FEB-201	by EES_PR	OD
		PENDING		on 12-FEB-2013	by EES_PR	OD
		WITHHOLD		on 30-AUG-201	2 by D. SMITH	H (HFD-323) 3017965321
		PENDING		on 09-AUG-201	2 by EES_PR	OD
		PENDING		on 18-JUL-2012	by EES_PR	OD
		WITHHOLD		on 25-APR-201	2 by EES_PR	OD
		WITHHOLD		on 18-APR-201	2 by EES_PR	OD
		PENDING		on 18-APR-201	2 by EES_PR	OD
		WITHHOLD		on 18-APR-201	2 by EES_PR	OD
		PENDING		on 14-DEC-201	1 by EES_PR	OD
		PENDING		on 17-NOV-201	1 by EES_PR	OD
		PENDING		on 16-NOV-201		
		PENDING		on 11-OCT-201		
		PENDING				
		FENDING		on 27-SEP-201	by EES_PRO	
Establishment:	CFN:	(b) (4)	FEI:	(b) (4)		
				(b) (4)		
DMF No:					AADA:	
Responsibilities:	DRUG SU	BSTANCE STABILITY	TEST	ER		
Profile:	CONTROL	L TESTING LABORAT	ORY		OAI Status:	NONE
Last Milestone:	OC RECO	MMENDATION				
Milestone Date:	(b) (4)				
Decision:	ACCEPTA	BLE				
Poson:	DISTRICT	RECOMMENDATION	I			
					a de como de como del como de c	

Er Nishment:	CFN: (b) (4) FEI: (b) (4)		
	(b) (4)		
DMF No:		AADA:	
Responsibilities:	FINISHED DOSAGE RELEASE TESTER		
Profile:	CONTROL TESTING LABORATORY	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	(b) (4)		
Decision:	ACCEPTABLE		
Reason:	BASED ON PROFILE		
Establishment:	CFN: (b) (4) (b) (4)		
	(*)		
DMF No:		AADA:	
Responsibilities:	FINISHED DOSAGE RELEASE TESTER		
Profile:	CONTROL TESTING LABORATORY	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	(b) (4)		
r on:	ACCEPTABLE		
Reason:	DISTRICT RECOMMENDATION		
Establishment:	CFN: (b) (4) (b) (4) (4)		
DMF No:		AADA:	
Responsibilities:	FINISHED DOSAGE RELEASE TESTER		
Profile:	CONTROL TESTING LABORATORY	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	(b) (4)		
Decision:	ACCEPTABLE		
Réason:	BASED ON PROFILE		

Ee*~hlishment:	CFN: F	EI: (b) (4)		
	(b) (4)			
DMF No:			AADA:	
Responsibilities:	FINISHED DOSAGE MANUFACTU			1015
Profile:	STERILE-FILLED SMALL VOLUME DRUGS	EPARENTERAL	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION			
Milestone Date:	(b) (4)			
Decision:	ACCEPTABLE			
Reason:	DISTRICT RECOMMENDATION			
Establishment:	CFN: (b) (4) F	El: (b) (4)		** **** * * * * * * * * * * * * * *
		(b) (4)		
DMF No:			AADA:	
Responsibilities:	FINISHED DOSAGE RELEASE TE	STER		
Profile:	CONTROL TESTING LABORATOR	RY	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION			
Milestone Date:	(b) (4)			
Γ `on:	ACCEPTABLE			
Reason:	DISTRICT RECOMMENDATION			
Establishment:	CFN: (b) (4) F	EI: (b) (4)		
	(b) (4)			
DMF No:			AADA:	
Responsibilities:	FINISHED DOSAGE RELEASE TE	STER		
Profile:	CONTROL TESTING LABORATOR	RY	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION			
Milestone Date:	(b) (4)			
Decision:	ACCEPTABLE			
Reason:	DISTRICT RECOMMENDATION			

Er ' 'ishment:	CFN: (b) (4) FEI: (b) (4) (b) (4)		
DMF No:		AADA:	
Responsibilities:	FINISHED DOSAGE MANUFACTURER		
Profile:	SMALL VOLUME PARENTERAL, LYOPHILIZED	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	(b) (4)		
Decision:	ACCEPTABLE		
Reason:	DISTRICT RECOMMENDATION		
Establishment:	CFN: (b) (4) FEI: (b) (4)		
	(b) (4)		
DMF No:		AADA:	
Responsibilities:	DRUG SUBSTANCE STABILITY TESTER	10.210	
Profile:	CONTROL TESTING LABORATORY	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	(b) (4)		
Г ул:	ACCEPTABLE		
Reason:	BASED ON PROFILE		
Establishment:	CFN: (b) (4) FEI: (b) (4)		
	(b) (4)		
DMF No:		AADA:	
Responsibilities:	DRUG SUBSTANCE MANUFACTURER	~~~~.	
Profile:	(b) (4)	OAI Status:	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	(b) (4)		
Decision:	ACCEPTABLE		
Reason:	DISTRICT RECOMMENDATION		

plication:	NDA 2022	07/000				Spons	or:	NAVIDEA	BIOPHARMS	
I. C	160							425 METF	O PL NORTH ST	E 450
prity.	1							DUBLIN, (OH 43017	
mp Date:	10-AUG-2	011				Brand	Name:	LYMPHOS	SEEK	
JFA Date:	10-SEP-2	012				Estab.	Name:			
ion Goal:						Generi	c Name:	Tilmanoce	pt	
trict Goal:	11-APR-2	012							; Ingredient; St FION SOLUTION;	rengths TILMANOCEPT; .25MG
A Contacts:	Y. LIU			Pro	ject Manage	er			30	17961926
	R. KASLI	WAL		Re	view Chemis	st			30	17961386
	E. LEUTZ	INGER		Tea	am Leader				30	17961399
arall Recommend	lation:		WITHHOLD		on 30-AL	JG-2012	by D. SMITH		(HFD-323)	3017965321
			PENDING		on 09-AL	JG-2012	by EES_PRO	D		
			PENDING		on 18-JU	L-2012	by EES_PRO	D		
			WITHHOLD		on 25-AF	PR-2012	by EES_PRO	D		
			WITHHOLD		on 18-AF	R-2012	by EES_PRO	D		
			PENDING		on 18-AF	R-2012	by EES_PRO	D		
			WITHHOLD		on 18-AF	R-2012	by EES_PRO	D		
			PENDING		on 14-DE	C-2011	by EES_PRO	D		
			PENDING		on 17-NC	OV-2011	by EES_PRO	D		
			PENDING		on 16-NC	OV-2011	by EES_PRO	D		
			PENDING		on 11-00	CT-2011	by EES_PRO	D		
			PENDING		on 27-SE	P-2011	by EES_PRO	D		
ablishment:	CFN	l:	(b) (4)	FEI	(b) (4		- <u> </u>			
						(b) (4)				
F No:							AADA:			
ponsibilities:	DRI	IG SUB	STANCE STAE	NUTY TES	TER					
file:			TESTING LAB				OAI Status:	NONE		
t Milestone:			MENDATION							
estone Date:		(b) (4	4)							
ision:	ACC	EPTAB	LE							
ison:			RECOMMENDA	TION						

ablishment:	CFN: (b) (4) FEI: (b) (4) (b) (4)	
F No:		AADA:
ponsibilities:		OAI Status: NONE
file:	CONTROL TESTING LABORATORY	UAI Status: NONE
t Milestone:		
estone Date:	(b) (4)	
sision:	ACCEPTABLE	
ison:	BASED ON PROFILE	
ablishment:	CFN: (b) (4) FEI: (b) (4) (b) (4)	
F No:	(b) (4)	AADA:
ponsibilities:	FINISHED DOSAGE RELEASE TESTER	
file:	CONTROL TESTING LABORATORY	OAI Status: NONE
t Milestone:	OC RECOMMENDATION	
estone Date:	(b) (4)	
;isi	ACCEPTABLE	
ison:	DISTRICT RECOMMENDATION	
ablishment:	CFN: (b) (4) FEI: (b) (4) (b) (4)	<u>, , , , , , , , , , , , , , , , , , , </u>
F No:		AADA:
ponsibilities:	FINISHED DOSAGE RELEASE TESTER	
file:	CONTROL TESTING LABORATORY	OAI Status: NONE
t Milestone:	OC RECOMMENDATION	
estone Date:	(b) (4)	
ision:	ACCEPTABLE	
ison:	DISTRICT RECOMMENDATION	

ablishment:	CFN:	FEI: (b) (4)		
	(b) (4)			
F No:			AADA:	
ponsibilities:	FINISHED DOSAGE MANUFACT	URER		
file:	STERILE-FILLED SMALL VOLUM DRUGS	IE PARENTERAL	OAI Status:	NONE
t Milestone:	OC RECOMMENDATION			
estone Date:	(b) (4)			
sision:	ACCEPTABLE			
ison:	DISTRICT RECOMMENDATION			
ablishment:	CFN: (b) (4)	FEI: (b) (4)		
		(b) (4)		
F No:			AADA:	
ponsibilities:	FINISHED DOSAGE RELEASE T	ESTER		
file:	CONTROL TESTING LABORATO	RY	OAI Status:	NONE
t Milestone:	OC RECOMMENDATION			
estr Date:	(b) (4)			
:isi	ACCEPTABLE			
ison:	DISTRICT RECOMMENDATION			
ablishment:	CFN: (b) (4)	FEI: (b) (4)		
	(b) (4)			
F No:			AADA:	
ponsibilities:	FINISHED DOSAGE RELEASE T	ESTER		
file:	CONTROL TESTING LABORATO	RY	OAI Status:	NONE
t Milestone:	OC RECOMMENDATION			
estone Date:	(b) (4)			
ision:	ACCEPTABLE			
ison:	DISTRICT RECOMMENDATION			

ablishment:	CFN:	(b) (4)	FEI:	(b) (4)			
					(b) (4)		
F No:						AADA:	
ponsibilities:	FINISHE	D DOSAGE MANUFAC	FURER				
file:	SMALL	OLUME PARENTERAL	, LYOPHILI	ZED		OAI Status:	NONE
t Milestone:	OC REC	OMMENDATION					
estone Date:		(b) (4)					
ision:	WITHHC	LD					
ISON:		T RECOMMENDATION	RICT				

ADMIN CLOSURE-IGNORE RECCOMEND

ablishment:	CFN: (b) (4) FEI: (b) (4) (b) (4)	
F No:		AADA:
ponsibilities:	DRUG SUBSTANCE STABILITY TESTER	
file:	CONTROL TESTING LABORATORY	OAI Status: NONE
t Milestone:	OC RECOMMENDATION	
estone Date:	(b) (4)	
sision:	ACCEPTABLE	
ison:	BASED ON PROFILE	
ablishment:	CFN: (b) (4) FEI: (b) (4)	
ablishment:	CFN: (b) (4) FEI: (b) (4) (b) (4)	
ablishment: F No:	(b) (4)	AADA:
	(b) (4)	AADA:
F No:	(b) (4) DRUG SUBSTANCE MANUFACTURER	AADA: OAI Status: NONE
F No: ;ponsibilities:	(b) (4) DRUG SUBSTANCE MANUFACTURER	
F No: ;ponsibilities: file:	(b) (4) DRUG SUBSTANCE MANUFACTURER (b) (4)	
F No: ;ponsibilities: file: :t Milestone:	(b) (4) DRUG SUBSTANCE MANUFACTURER (b) (4) OC RECOMMENDATION	